ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

NCI’s New Policy On Costly Research

December 10, 1993

Alimta Granted Approval As NSCLC Continuation Therapy

November 25, 2011

President’s FY 1992 Budget Seeks $1.81 Billion For NCI, 5.6% Increase, But $800M Below Byspass

February 8, 1991

DES Exposure Studies Below Payline; NCI Considers Contracts

March 6, 1992

Increase Cancer Center Grants More Than R01s, SPOREs, Report Tells NCI

February 28, 2003

Obama Calls for Bigger Investment in Science, GOP Plans Cuts

January 28, 2011